Dongwha Pharm.Co.,Ltd (000020) Fair Value & Analysis
Healthcare · KR · Market cap 156B KRW
Fair value as of: Jun 25, 2026
From 14 valuation models · updated 5 days ago
Share price −19.1% over the past month.
Price vs Fair Value (12 months)
12‑month range 4,810 KRW – 7,085 KRW · fair‑value band 5,171 KRW – 8,618 KRW · the 4,810 KRW price screens below the 6,894 KRW fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Dongwha Pharm.Co.,Ltd (000020) currently trades at 4,810 KRW, while our model-based Fair Value estimate is 6,894 KRW — implying the stock looks roughly 43.3% undervalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Dongwha Pharm.Co.,Ltd generated revenue of 298B KRW at a net margin of 15.5%. Revenue grew 3.9% year over year. It earns a return on equity of 16.6%. Net debt stands at 88.9B KRW. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, dermatological, mouth and tooth, hepatic protectors, nutrients, tonics, topic analgesic, antihistamines, sore throat, and others; quasi drugs; health subsidiary foods; foods and drinks; and cosmetics. The company also exports its products. Dongwha Pharm.Co.,Ltd was founded in 1897 and is headquartered in Seoul, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Dongwha Pharm.Co.,Ltd reported revenue of 496B KRW in FY2025 versus 293B KRW in FY2021, a compound +14.1%/yr. Reported net income was 8.7B KRW in FY2025, compounding −16.5%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 466.40 | kr 213.97 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Dongwha Pharm.Co.,Ltd (000020) undervalued?
What is the fair value of 000020?
What is the quality score of 000020?
What is the revenue of Dongwha Pharm.Co.,Ltd (000020)?
What is the net profit margin of 000020?
Does Dongwha Pharm.Co.,Ltd pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.